Piecing the Puzzle Together: Docetaxel Cycles and Current Considerations in the Treatment of Metastatic Castration-Resistant Prostate Cancer.

Piecing the Puzzle Together: Docetaxel Cycles and Current Considerations in the Treatment of Metastatic Castration-Resistant Prostate Cancer.

Cancer Biol Ther. 2017 Feb 25;:0

Authors: Feinman HE, Price DK, Figg WD

Abstract
Docetaxel is the current first line therapy for metastatic castration-resistant prostate cancer (mCRPC), but there is no standard number of docetaxel cycles given to patients. In their post hoc analysis of the Mainsail study, de Morrée et al. show that the number of docetaxel cycles administered to a patient is a significant factor contributing to overall survival. These findings warrant further investigation into the standardization of the number of docetaxel cycles administered.

PMID: 28278075 [PubMed - as supplied by publisher]

http://ift.tt/2msYo4b